Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
(Get Rating)Investment analysts at StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a report issued on Saturday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Stocknews.com 的投資分析師開始對股票的覆蓋 性 (納斯達克:奧迪 — 獲得評級) 在星期六發出的報告中。該經紀公司對該生物製藥公司的股票設定了「持有」評級。
Separately, Piper Sandler cut shares of Otonomy from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $3.00 to $0.50 in a research report on Thursday, October 13th.
另外，派珀·桑德勒（Piper Sandler）在 10 月 13 日（星期四）的一份研究報告中，將 Otonomy 的股票從「超重」評級降至「中性」評級，並將公司的價格目標從 3.00 美元降至 0.50 美元。
Otonomy Price Performance
Otonomy 的價格表現
NASDAQ:OTIC opened at $0.08 on Friday. The firm has a 50-day moving average of $0.11 and a two-hundred day moving average of $0.71. The stock has a market cap of $4.40 million, a P/E ratio of -0.10 and a beta of 1.31. Otonomy has a 1-year low of $0.06 and a 1-year high of $2.59.
納斯達克：奧迪週五以 0.08 美元開業。該公司的 50 天移動平均線為 0.11 美元，兩百日移動平均線為 0.71 美元。該股的市值為 440 萬美元，市盈率為 -0.10，貝塔值為 1.31。Otonomy 的 1 年低點為 0.06 美元，1 年高點為 2.59 美元。
Institutional Investors Weigh In On Otonomy
機構投資者對 Otonomy 的權衡
About Otonomy
關於「音樂」
(Get Rating)
(取得評分)
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Otonomy, Inc 是一家生物製藥公司，在美國開發神經病學治療藥物。該公司提供 OTO-313（N-甲基-D-天冬氨酸受體拮抗劑 gacyclidine）的可持續暴露配方，用於治療耳鳴的第二期臨床試驗；OTO-413（一種腦源性神經營養因子的持續暴露配方），用於修復耳蝸突觸病和聽力噪音困難的 IIA 期臨床試驗。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免費獲取有關 OTONNOMY 的研究報告
- 市場節拍：評論中的一周
- 這些鋼鐵製造商應該在您的 2023 觀察名單中佔有一席之地
- 通貨膨脹冷卻，S&P 500 現在去哪裡
- 辛塔斯用運營槓桿擊敗通貨膨脹
- 您購買 Palantir 的決定可能只是時間問題
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Otonomy 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。